Thalidomide (methylamino)acetaldehyde is an E3 ubiquitinase ligand-linker conjugate. Thalidomide (methylamino)acetaldehyde can be used to synthesize WZH-17-002.

E913 is a CCR5 antagonist that competes with the binding of antibodies to CCR5 which recognize the C-terminal half of the second extracellular loop (ECL2B) of CCR5. E913 can specifically block the binding of macrophage inflammatory protein-1alpha (MIP-1alpha) to CCR5 (IC50 = 0.002 μM) and MIP-1alpha-elicited cellular Ca2+ mobilization (IC50 = 0.02 μM). E913 inhibits the replication of laboratory and primary R5 HIV-1 strains as well as various multidrug-resistant monocyte/macrophage tropic (R5) HIV-1 (IC50 = 0.03-0.06 μM). E913 can be used for the research of infection, such as HIV-1 infection.

E3 Ligase Ligand-linker Conjugate 212 is a PROTAC E3 ligase-linker conjugate that can be used for synthesis of PROTACs, such as PROTAC IKZF1/3 Degrader-1. PROTAC IKZF1/3 Degrader-1 is a potent IKZF1/3 PROTAC degrader with neuroprotective activity.

FE100726 (Compound 39) is a Cholecystokinin 2 (CCK2) receptor agonist. FE100726 has a superior binding capacity on CCK2 receptor. FE100726 can induce gastric acid secretion in anaesthetized rat models. FE100726 can be used for diabetes research.

ARN25657 is a dual-acting D3R/GSK-3β modulator. ARN25657 has both partial D3R agonist activity (EC50 = 15.2 nM, Ki =1.5 nM) and potent GSK-3β inhibitor activity (IC50 = 19.3 nM). ARN25657 exhibits excellent GSK-3β selectivity over FYN, PKA, and CDK5/p35. ARN25657 inhibits P-glycoprotein (P-gP)-mediated acetoxymethyl calcein efflux and improves in vitro ADME properties while maintaining a balanced dual-target profile. ARN25657 is useful for studying bipolar disorder and related neuropsychiatric disorders.

Aurora kinase inhibitor-14 (Compound 79) is an orally active and highly selective inhibitor of Aurora kinases with IC50 values of 0.5 nM and 1.2 nM for Aurora A and Aurora B, respectively. Aurora kinase inhibitor-14 binds to the ATP-binding site of Aurora kinases to block chromosome segregation during mitosis and induce apoptosis in tumor cells. Aurora kinase inhibitor-14 is promising for research of various solid tumors and hematological malignancies, such as non-small cell lung cancer, breast cancer, and acute myeloid leukemia.

MNFA is a derivative of Monofluoroacetic acid. MNFA is an effective pesticide.

KD-027 (SLx-2101) is a Phosphodiesterase 5 (PDE5) inhibitor. KD-027 can be used for endothelial dysfunction, and hypertension research.

AHN 070 is an irreversible peripheral benzodiazepine receptor (PBR) ligand. AHN 070 can bind to PBR with nanomolar affinity and is pH-dependent. AHN 070 can be used for studying the structure and function of PBR.

MK-8389 is an orally active LMW allosteric FSH receptor agonist. MK-8389 affects thyroid function.

DNK-333 is a potent and balanced dual NK1 and NK2 receptor antagonist with IC50 values of 4.8 nM and 5.5 nM, respectively. DNK-333 blocks the Neurokinin A (NKA)-induced bronchoconstriction in asthma.

TKA-731 is an NK1 receptor antagonist. TKA-731 can reverse mechanical hyperalgesia. TKA-731 can be used for research on neuropathic pain.

FKBP12 ligand-3 (compound dj) is a high-affinity ligand targeting FKBP12. FKBP12 ligand-3 can be used to selectively enhance the binding of heterobifunctional molecules to BRD4, enriching the drug intracellularly through the "CellTrap" effect to form a ternary complex of FKBP12-ligand-BRD4. This ternary complex has inhibitory activity against BRD4, thereby inhibiting the expression of BRD4 target genes (such as MYC) and inducing tumor cell death. FKBP12 ligand-3 can be used for selective cancer research based on differences in intracellular presenter protein levels.

EGFR ligand-14-PEG3-Boc contains EGFR ligand and linker. EGFR ligand-14-PEG3-Boc can be used for the synthesis of SJF-1521.

4-DTM-phenoxy-PEG4-CH2COOH (Formula 3) is a cleavable PEG-based ADC linker that can be used in the synthesis of antibody-drug conjugates (ADCs).

Di(4-morpholine-amide)-4-DTM-phenoxy(3,5-F)-PEG4-CH2COOH (compound BL) is a cleavable PEG-based ADC linker that can be used in the synthesis of antibody-drug conjugates (ADCs).

DBCO-PEG3-Glu-VC-PABC-MMAF (compound s19b) is a drug-linker conjugate for ADC by using the tubulin inhibitor, MMAF, linked via cathepsin cleavable DBCO-PEG3-Glu-VC-PABC. DBCO-PEG3-Glu-VC-PABC-MMAF can be used in the synthesis of antibody-drug conjugates (ADCs).

TBK1 ligand 2-C-O-C4-O-C3-O-C-amide is a conjugate of TBK1 ligand and linker, which can be used in the synthesis of PROTAC TBK1 degrader-2.

PROTAC BRD4 ligand-1-NH-PEG-phenol-PEG-COOtBu is an Target Protein Ligand-Linker Conjugate that incorporates a ligand for BRD4 and a PROTAC linker. PROTAC BRD4 ligand-1-NH-PEG-phenol-PEG-COOtBu can be used for synthesis of PROTAC BRD4 Degrader-14.

NH2-PEG-phenol-PEG-COOtBu is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC BRD4 Degrader-14.

KD025m1 is a novel selective ROCK2 inhibitor. KD025m1 has good anti obesity, improved insulin sensitivity, and blood glucose control effects. KD025m1 can be used to study metabolic diseases such as diabetes and obesity.

Nef ligand-2 is a binder of Nef. Nef ligand-2 is Ligands for E3 Ligase. Nef ligand-2 is the Nef Binder portion of FC-14369.

Phenyl-glutarimide 4'-oxyacetic-amide-C5-amide-Boc is an E3 ligase ligand-linker conjugate used in the synthesis of PROTAC SJ995973.

Thalidomide-OCH2-amide-PEG2-C2-Boc is an E3 ligase ligand-linker conjugate containing a cereblon (CRBN) ligand for E3 ubiquitin ligase and a linker. Thalidomide-OCH2-amide-PEG2-C2-Boc can be used to synthesize PROTAC SARS-CoV-2 Degrader-1.

PD 172760 is a selective D4 receptor antagonist. PD 172760 along with the action of other neurotransmitter receptors may be important in treating psychosis.

LacNAc-VC-PAB-MMAE is a component of an Antibody-Drug Conjugate (ADC). LacNAc-VC-PAB-MMAE is assembled onto the N-glycosylation site of Trastuzumab by WT Endo-S2.

DD-04-038 is a molecular glue degrader. DD-04-038 induces proteins (such as IKZF1/3, ZBED3 and PATZ1) to bind to CRBN, promoting their ubiquitination and degradation.

ALK ligand-Linker Conjugate 1 is a ALK ligand-linker conjugate that can be used for synthesis of PROTAC ALK degrader-4.

NSC 850745 is a selective and potent c-Met/STAT3 inhibitor with IC50 values of 210 and 670 nM. NSC 850745 can inhibit cell proliferation, induce G2/M phase arrest and induce apoptosis. NSC 850745 can downregulate AKT-1, VEGF and Bcl-2 expression and upregulate p53, Bax and caspase expression. NSC 850745 can be used for the research of cancer, such as leukemia and colon cancer.

SMARCA2/4 Ligand-Linker Conjugate 2 is a target protein ligand-linker conjugate that can be used to synthesize PROTAC AU-15330.